Herbert I. Hurwitz
0000-0003-3242-9197
Publication & Citation Trends
Publications
0 total
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)
Cited by 5
Semantic Scholar
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Subjects.
Cited by 0
Semantic Scholar
Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study
Cited by 0
Semantic Scholar
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) OA
Cited by 19
Semantic Scholar
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study OA
Cited by 74
Semantic Scholar
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. OA
Cited by 241
Semantic Scholar
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Cited by 14
Semantic Scholar
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer OA
Cited by 23
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(252)
Cancer Treatment and Pharmacology
(148)
Cancer Genomics and Diagnostics
(96)
Gastric Cancer Management and Outcomes
(82)
Pancreatic and Hepatic Oncology Research
(71)
Affiliations
Université Claude Bernard Lyon 1
Boston University
Northwestern University
University of North Carolina at Chapel Hill
Roche (Switzerland)